Genascence Corporation

Revolutionizing treatment for musculoskeletal diseases.

[Genascence Corporation @genascence]

Genascence’s founder, CEO @ThomasChalberg, PhD, participated in a panel at the “Financing Biotech Innovation” event presented by @FinancialTimes. #geneticmedicine #genetherapy https://t.co/09YlV9Rh2L

[Genascence Corporation @genascence]

12-month safety and PD data from our DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class #geneticmedicine for knee #OA, will be featured in a late-breaking e-poster (#459) at #ICRS25 18th World Congress Joint Revolution. https://t.co/KJ1NvaAJP0

[Genascence Corporation @genascence]

Genascence CSO and co-founder Annahita Keravala will present 12-month data from the DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class #geneticmedicine for knee #OA, in an oral presentation at #ESGCT25 on Thurs. 10/9. #genetherapy https://t.co/lcpdhYpfKJ

[Genascence Corporation @genascence]

Genascence’s founders – CEO Tom Chalberg and CSO Annahita Keravala - are featured in PharmaShots CXO podcast that highlights our lead program, GNSC-001, a #geneticmedicine for knee #OA. #genetherapy https://t.co/2iCcox8wKS

[Genascence Corporation @genascence]

Excited to share an invited editorial by our founders published in Molecular Therapy about expanding the scope of #genetherapy to treat common diseases like #osteoarthritis (#OA) and features GNSC-001, a potential first-in-class gene therapy for knee OA. https://t.co/GNklh04dq0

[Genascence Corporation @genascence]

Genascence is thrilled to announce the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class #genetherapy blocking interleukin 1 (IL-1) for the treatment of knee #osteoarthritis (#OA). https://t.co/QDj6UkgAf1

[Genascence Corporation @genascence]

Check out this TIDES Global article, “The 30-year journey to a gene therapy for ‘incurable’ #osteoarthritis” featuring our co-founder Chris Evans, Ph.D., who shares the path to discovering GNSC-001, a potential first-in-class gene therapy for knee OA. https://t.co/0134x97CNH

[Genascence Corporation @genascence]

Genascence is proud to sponsor the 2025 Cutting Edge #Osteoarthritis (#OA) meeting taking place next week, June 30-July 1, 2025 in Oxford, England. https://t.co/R51z5Oe49N #genetherapy

[Genascence Corporation @genascence]

Genascence is excited to announce results from the first-in-human Phase 1 clinical trial evaluating GNSC-001, a #geneticmedicine for knee #OA, were published today in @ScienceMagazine Translational Medicine. https://t.co/uCNqxBjXKH

[Genascence Corporation @genascence]

Annahita Keravala, PhD, Genascence’s CSO and co-founder, presented six-month data analysis from the Phase 1b DONATELLO clinical trial evaluating GNSC-001 in a poster at #ASGCT25. GNSC-001 is a potential first-in-class #genetherapyblocking IL-1 for the treatment of knee #OA.

[Genascence Corporation @genascence]

Genascence CSO and co-founder Annahita Keravala, PhD will present 6-month data from the DONATELLO clinical trial evaluating GNSC-001 at #ASGCT25 today (poster 1849; abstract AMA616). GNSC-001 is a potential first-in-class #genetherapy for knee #OA. https://t.co/UfviehDAIX

[Genascence Corporation @genascence]

Genascence Phase 1b DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class #genetherapy blocking interleukin 1 (IL-1) for the treatment of knee #OA met the primary end key secondary endpoints. Read more at https://t.co/UfviehDAIX

[Genascence Corporation @genascence]

Genascence’s CMO Jeymi Tambiah was a featured speaker at the 25th WCO-IOF-ESCEO where he presented positive 6-month interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a #geneticmedicine for knee #OA.

[Genascence Corporation @genascence]

Our CEO and founder, Tom Chalberg, spoke with Ben Comer and Matthew Pillar on the #BusinessofBiotech podcast to discuss his experience and how Genascence is leading a renaissance in #genetherapy for common diseases like #OA. Tune in here: https://t.co/vWJZBlisQV

[Genascence Corporation @genascence]

Genascence was featured this week by Drug Discovery & Development that highlights our lead program, GNSC-001, a #geneticmedicine for knee #OA. disability. GNSC-001 has received Fast Track Designation with the #FDA. #genetherapy https://t.co/nIEJInAA3i

[Genascence Corporation @genascence]

Genascence was featured this week by Drug Discovery & Development that highlights our lead program, GNSC-001, a #geneticmedicine for knee #OA. disability. GNSC-001 has received Fast Track Designation with the #FDA. #genetherapy https://t.co/nIEJInAA3i

[Genascence Corporation @genascence]

Genascence is excited to announce positive interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a #geneticmedicine for knee #OA, a progressive joint disease that is a leading cause of disability. https://t.co/d7mAkgN7xU

[Genascence Corporation @genascence]

Genascence is excited to share the #FDA has granted Fast Track designation to GNSC-001, a potential first-in-class #genetherapy for the treatment of patients with #osteoarthritis (#OA) of the knee. For more information, read here: https://t.co/9rvhjbOsDS

[Genascence Corporation @genascence]

Genascence is pleased to welcome Jeymi Tambiah as our new CMO. An accomplished physician-scientist, Jeymi brings more than 15 years’ biopharmaceutical industry experience in the areas of #osteoarthritis, immunology, oncology, and neuroscience. https://t.co/kyFZRnlbtG

[Genascence Corporation @genascence]

Genascence is excited to present at the 2024 Biocom California Global Life Science Partnering & Investor Conference being held this week. CEO and co-founder
@ThomasChalberg will present a corporate overview on Wednesday, 2/28/24 at 11:51aPT. #genetherapy #osteoarthritis #OA